⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640058 | 0.92 | KDM1A (0.32) | — | |
| SCHEMBL6291549 | 0.90 | KDM1A (0.31) | — | |
| SCHEMBL6291550 | 0.90 | KDM1A (0.31) | — | |
| SCHEMBL6294995 | 0.90 | KDM1A (0.31) | — | |
| SCHEMBL23532623 | 0.90 | KDM1A (0.31) | — | |
| SCHEMBL23532425 | 0.90 | KDM1A (0.31) | — | |
| SCHEMBL2519259 | 0.79 | — | — | |
| SCHEMBL10429771 | 0.79 | P2RX7 (0.33) | — | |
| SCHEMBL10429772 | 0.79 | P2RX7 (0.33) | — | |
| SCHEMBL3763968 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4413085-A1 | SILICON-AND ZINC-CONTAINING COUPLING AGENT FOR CELLULOSIC MATERIAL-POLYMER COMPOSITES | Arkema, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| CN-118318010-A | Coupling agents containing silicon and zinc for cellulosic material-polymer composites | 阿科玛股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023059592-A1 | SILICON-AND ZINC-CONTAINING COUPLING AGENT FOR CELLULOSIC MATERIAL-POLYMER COMPOSITES | ARKEMA INC. (US) | 2023-04-13 | — | — | WO | claimed |
| US-20060079099-A1 | Ultra low k plasma enhanced chemical vapor deposition processes using a single bifunctional precursor containing both a SiCOH matrix functionality and organic porogen functionality | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2006-04-13 | — | — | US | claimed |
| US-20250346581-A1 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | SCRIPPS RESEARCH INST (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4413085-A1 | SILICON-AND ZINC-CONTAINING COUPLING AGENT FOR CELLULOSIC MATERIAL-POLYMER COMPOSITES | Arkema, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118318010-A | Coupling agents containing silicon and zinc for cellulosic material-polymer composites | 阿科玛股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023141593-A2 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023059592-A1 | SILICON-AND ZINC-CONTAINING COUPLING AGENT FOR CELLULOSIC MATERIAL-POLYMER COMPOSITES | ARKEMA INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20230034883-A1 | MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION | CONSIGLIO NAZIONALE DELLE RICERCHE (60%) (IT) | 2023-02-02 | — | — | US | disclosed |
| EP-4076729-A1 | MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION | Consiglio Nazionale Delle Ricerche (IT) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076730-A1 | MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION | Consiglio Nazionale Delle Ricerche (IT) | 2022-10-26 | — | — | EP | disclosed |
| US-6951942-B2 | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LABORATORIES (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6506766-B1 | A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid | ABBOTT LABORATORIES | 2003-01-14 | — | — | US | disclosed |
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1053239-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999041256-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1999-08-19 | — | — | WO | disclosed |